Entry |
|
Name |
Cabotegravir sodium (JAN/USAN); Vocabria (TN) |
Product |
|
Formula |
C19H16F2N3O5. Na
|
Exact mass |
427.0956
|
Mol weight |
427.334
|
Structure |

|
Simcomp |
|
Remark |
Product (DG01628): | D10549<US> |
Product (mixture): | D11966<US> |
|
Efficacy |
Antiviral, HIV integrase inhibitor |
Disease |
|
Target |
HIV-1 integrase |
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AJ Integrase inhibitors
J05AJ04 Cabotegravir
D10549 Cabotegravir sodium (JAN/USAN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10549
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10549
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 30
1 C8y C 17.9200 -17.4300
2 N4y N 17.9200 -16.0300
3 C8x C 19.1100 -15.3300
4 C8y C 20.3700 -16.0300
5 C8y C 20.3700 -17.4300
6 C8y C 19.1100 -18.1300
7 C5x C 16.7300 -18.1300
8 N1y N 15.4700 -17.4300
9 C1y C 15.4700 -16.0300
10 C1x C 16.7300 -15.3300
11 O5x O 16.7300 -19.5300
12 O1a O 19.1100 -19.5300 #-
13 O5x O 21.5600 -18.1300
14 C5a C 21.5600 -15.3300
15 N1b N 22.7500 -16.0300
16 O5a O 21.5600 -13.9300
17 C1b C 23.9400 -15.3300
18 C8y C 25.1300 -16.0300
19 C8x C 26.3200 -15.3300
20 C8x C 27.5800 -16.0300
21 C8y C 27.5800 -17.4300
22 C8x C 26.3900 -18.1300
23 C8y C 25.1300 -17.4300
24 X F 23.9400 -18.1300
25 X F 28.7700 -18.1300
26 O2x O 14.1400 -15.6100
27 C1x C 13.3000 -16.7300
28 C1y C 14.1400 -17.8500
29 C1a C 13.7200 -19.1800
30 Z Na 21.7000 -20.8600 #+
BOND 32
1 1 2 1
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 1
6 1 6 2
7 1 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 2 10 1
12 7 11 2
13 6 12 1
14 5 13 2
15 4 14 1
16 14 15 1
17 14 16 2
18 15 17 1
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 18 23 1
26 23 24 1
27 21 25 1
28 9 26 1
29 26 27 1
30 27 28 1
31 8 28 1
32 28 29 1 #Up
|